Health Economics›Renal cell carcinoma›Metastatic disease second-line

Metastatic disease second-line

Renal cell carcinoma · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cabozantinib monotherapy Variant #01	—	R 151 638	28d	~9.0 mo	~16.2 mo	~2	~R 303 276 PFS proxy · indirect	8
Sorafenib monotherapy Variant #04	—	R 37 339	28d	3.9 mo	—	25	R 549 414 PFS proxy	1
Cyclophosphamide and Fludarabine (FC), then allo HSCT Variant #01 Partial	—	R 28 134	—	—	—	~1	~R 28 134 indirect	—
Everolimus monotherapy Variant #01	—	R 18 360	28d	~7.9 mo	—	~2	~R 36 719 PFS proxy · indirect	1
Sunitinib monotherapy Variant #01	—	R 15 867	42d	~9.2 mo	—	~2	~R 31 733 PFS proxy · indirect	2
Interferon alfa-2a and Isotretinoin Variant #01 Partial	—	R 250	7d	—	17.3 mo	4	R 1 000 PFS proxy	—
Interferon alfa-2c monotherapy Variant #01 Partial	—	—	7d	—	—	~2	—	—
Interferon alfa-2a monotherapy Variant #01 Partial	—	—	7d	—	~13.0 mo	~2	—	4
Megestrol monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—

9 of 9 regimens shown